What is Ardelyx?
Ardelyx is dedicated to the discovery, development, and commercialization of first-in-class medicines. The company's approved product, IBSRELA® (tenapanor), is available in the United States and Canada. Ardelyx is also advancing XPHOZAH® (tenapanor), a promising candidate for hyperphosphatemia management in adult patients with chronic kidney disease (CKD) on dialysis, which has successfully completed three Phase 3 trials. The company's consistent access to significant capital indicates a strong market belief in its therapeutic approach and development capabilities.
How much funding has Ardelyx raised?
Ardelyx has raised a total of $522.5M across 11 funding rounds:
Series A
$26M
Series B
$30M
Multiple Rounds
$100.8M
Share Placement
$77.8M
Stock Offering
$80.4M
Share Placement
$110M
Debt
$50M
Debt
$27.5M
Other Financing Round
$20M
Series A (2008): $26M with participation from CMEA Ventures
Series B (2011): $30M led by New Enterprise Associates, Amgen Business Development, and CMEA Ventures
Corporate Investment (2014): $15M supported by AstraZeneca
Corporate Investment (2014): $25M featuring AstraZeneca
Stock Issuance/Offering (2014): $60.8M backed by Undisclosed
Share Placement (2015): $77.8M with participation from Sabby Capital, Cormorant Asset Management, Broadfin Capital, RA Capital Advisors, Rock Springs Capital, Foresite Capital Management, and New Enterprise Associates
Stock Issuance/Offering (2016): $80.4M led by Undisclosed
Share Placement (2016): $110M supported by Deerfield, EcoR1 Capital, Rock Springs Capital, DAFNA Capital Management, Perceptive Advisors, First Manhattan Co., RA Capital Management, Quadrille Capital, Cormorant Asset Management, New Enterprise Associates, and FutureFund
Debt (2018): $50M featuring Bridge Bank and Solar Capital
Debt (2022): $27.5M backed by SLR Capital Partners
Other Financing Round (2022): $20M with participation from HealthCare Royalty Partners
Key Investors in Ardelyx
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on helping entrepreneurs build businesses, particularly within the technology and life sciences sectors.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm that provides financial resources to support innovative companies in the biotech and allied sectors, driven by a deep focus on fundamental scientific principles.
RA Capital Management
RA Capital Management is a multi-stage investment manager specializing in public and private healthcare and life science companies, with a focus on evidence-based investing to improve patient lives.
What's next for Ardelyx?
With a robust funding history and a focus on critical therapeutic areas, Ardelyx is well-positioned for continued growth and the expansion of its commercial reach. The recent major strategic investment suggests a phase of scaling operations, potentially including further clinical development, regulatory submissions, and market penetration for its existing and pipeline assets. The company's trajectory points towards solidifying its position as a key player in the biopharmaceutical landscape, driven by its commitment to addressing complex health challenges.
See full Ardelyx company page
